AGXT and Alzheimer disease: One such study by Geekiyanage H et al. discovered a loss of miR-137, miR-181c, miR-9, and miR-29a/b-1 in AD, which could increase SPT and in turn Aβ levels, which represent intrinsic mechanisms for elevated risk of AD, suggesting the use of miRNAs as potential therapeutic targets for sporadic AD [47].